Glad that progress has been made reducing the company's exposure to vaccine research. I think that sharp focus should be held on the current drivers eg ADAPT , TAVR and research into the many other areas that our core CardioCel technology can be applied to.
For me, Admedus Vaccines always felt like a hole that the company threw money into ...how long is a piece of string?
“This arrangement will greatly enhance our resources and allow myself, and the team, to accelerate our projects as we delve further into the science that may ultimately lead to the development of groundbreaking vaccines". Professor Ian Frazer.
Glad that progress has been made reducing the company's exposure...
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.05 |
Change
-0.100(0.66%) |
Mkt cap ! $289.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $55.60K | 3.661K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13 | $15.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 1 | 1 |
View Market Depth
| Last trade - 14.52pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |